Table 1. Summary of Cytotoxicity Parameters for Compound 3 from a Five-Dose Screen against the NCI’s Panel of 60 Human Cancer Cell Linesa.
| cancer | N | GI50, μM | IC50, μM | LC50, μM |
|---|---|---|---|---|
| leukemia | 3 | 1(1) | 5(1) | >100 |
| non-small cell lung | 9 | 6(5) | 15(13) | 97(6) |
| colon | 7 | 7(5) | 10(6) | 89(16) |
| CNS | 6 | 3(2) | 10(8) | 50(32) |
| melanoma | 9 | 8(5) | 27(20) | >100 |
| ovarian | 7 | 11(8) | 19(14) | 94(11) |
| renal | 8 | 14(12) | 25(21) | 89(24) |
| prostate | 2 | 7(4) | 16(11) | >100 |
| breast | 6 | 5(4) | 17(14) | 57(38) |
| average | 57b | 7(4) | 16(7) | 86(19) |
a
Abbreviations: N, number of cell lines within each cancer category; GI50, compound concentration effecting 50% growth inhibition; IC50, compound concentration effecting 100% growth inhibition; LC50, compound concentration that induces 50% cell death.
b
Total number of cell lines used. Estimated standard deviations are given in parentheses; large values indicate variable susceptibility of a specific group of cell lines to the test compound (see Figure S41).